RayzeBio logo

RayzeBio Funding & Investors

RayzeBio is focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes. As the emerging leader in radiopharmaceuticals, RayzeBio is developing an innovative robust pipeline against validated oncology drug targets to deliver radioisotopes that emit alpha particles such as Actinium-225.

rayzebio.com

Total Amount Raised: $418,000,000

RayzeBio Funding Rounds

  • Series D

    $160,000,000

    Series D Investors

    Sofinnova
    Viking Global Investors
    Wellington Management
    Sands Capital Management
    Laurion Capital Management
    ABG
    Soleus Capital
  • Series C

    $108,000,000

    Series C Investors

    Venrock Healthcare Capital Partners
    TCG Crossover Management
    Viking Global Investors
    Cormorant Asset Management
    Alexandria Venture Investments
    Acuta Capital Partners
    Versant Ventures
    Deerfield Management
    venBio Partners
    Vivo Capital
    Samsara BioCapital
    LifeSci Venture Partners
    Redmile Group
    OrbiMed Advisors
    Logos Global Management
    Perceptive Advisors
  • Series B

    $105,000,000

    Series B Investors

    Venrock Healthcare Capital Partners
    venBio Partners
    Viking Global Investors
    Redmile Group
    OrbiMed Advisors
    Alexandria Venture Investments
    Samsara BioCapital
    Cormorant Asset Management
    Logos Global Management
    LifeSci Venture Partners
    Versant Ventures
  • Series A

    $45,000,000

    Series A Investors

    venBio Partners
    Versant Ventures
    Samsara BioCapital
  • IPO

    Unknown

Funding info provided by Diffbot.